Citation Tools
PDFLate-Breaking Abstracts
Clinical Trial Completed
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)